WALTHAM, Mass., August 3, 2020 – Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapeutics for patients with serious muscle diseases, today announced that it has appointed Susanna High, MBA, as its chief operating officer. Ms. High has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies.
“Susanna’s demonstrated success at innovative biotech companies will be an incredible asset to Dyne as we pursue our goal of building the world’s leading muscle disease company,” said Joshua Brumm, president and chief executive officer of Dyne. “I look forward to partnering with Susanna and drawing on her depth of experience, particularly in rare diseases, as we work to develop and commercialize modern oligonucleotide therapeutics for serious muscle diseases. I am thrilled to welcome Susanna to the Dyne family.”
In her most recent position, Ms. High served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Ms. High worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Ms. High holds an M.S. in economics and business management from Bocconi University in Italy and an MBA from the MIT Sloan School of Management.
“The progress Dyne has made in its lead programs underscores the potential of the FORCE™ platform and the company’s commitment to transforming the treatment opportunities for individuals living with serious muscle diseases,” said Ms. High. “This is an exciting time for Dyne as their programs advance towards the clinic, and I am honored to join this committed leadership team to develop potentially life-changing therapies.”
Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.
Ten Bridge Communications
Stephanie Simon, (617) 581-9333